Clinical trials of QazVac vaccine successfully completed
The strain composition of the Kazakh vaccine QazVac is planned to be modernized. The Wuhan strain of the coronavirus is expected to be changed to the Delta strain. Director General of the Scientific Research Institute for Biological Safety Problems Kunsulu Zakarya announced this at a press briefing. The third phase of clinical trials of the QazVac vaccine has been completed in the summer. However, the results will be known in at least six months. According to Zakarya, the research of the first domestic antiviral drug was successful. 3,000 people took part in the study. Now, Kazakh scientists are preparing an article with the research results, which will be published in a high-ranking scientific journal.
“We will send the conclusion, the expert opinion to the editorial office of the journal. Our article has already been reviewed for six months, and we think that we will have our publication by the end of the year. All clinical studies were completed. On July 9 we collected the last analyzes, after which, until the end of July the statistical analysis of a huge data collection was processed,” Zakarya said.
Translation by Saule Mukhamejanova
Editing by Galiya Khassenkhanova